文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

肛周脓肿手术引流后阿莫西林/克拉维酸预防肛瘘发生的疗效(PERIQxA研究):多中心随机双盲临床试验研究方案

Efficacy of amoxicillin/clavulanic acid after surgical drainage of perianal abscess in the prevention of the development of anal fistula (PERIQxA study): study protocol for a multicenter randomized, double-blind clinical trial.
PubMed 文献 · Trials · 2024-02-15

PERIQxA研究为多中心、随机、双盲对照试验,计划纳入286例成人肛周脓肿手术引流后患者,按1:1随机分配至阿莫西林/克拉维酸875/125 mg每日三次共7天组或安慰剂组。主要结局为术后及随访6个月内肛瘘发生率,旨在评估抗生素预防肛瘘的疗效与安全性。

要点

  • 肛周脓肿切开引流后肛瘘发生率约为26-37%。
  • 计划纳入286例成人,1:1随机分入阿莫西林/克拉维酸组或安慰剂组。
  • 主要结局为术后及随访6个月内肛瘘发生百分比。

核心结论

  • 研究旨在评估肛周脓肿手术引流后使用抗生素对肛瘘发生的预防效果,作者期望结果有助于明确抗生素在肛周脓肿治疗中的潜在作用。

研究设计与样本

  • 多中心、随机、双盲对照试验,计划纳入286例成人患者,按1:1随机分配至实验组(阿莫西林/克拉维酸875/125 mg每日三次,共7天)或对照组(安慰剂)。

主要发现

  • 肛周脓肿切开引流后肛瘘发生率约为26-37%;抗生素预防肛瘘的作用此前研究结果矛盾且存在方法学局限,本研究假设阿莫西林/克拉维酸可降低肛瘘发生率。

关键数值与推荐

  • 实验组:阿莫西林/克拉维酸875/125 mg每日三次,共7天;对照组:安慰剂;主要结局指标:术后及随访6个月内发生肛周瘘的患者百分比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anorectal fistula, which is a relatively common pathology, is the chronic manifestation of the acute perirectal process that forms an anal abscess. The development of a fistula after incision and drainage of an anal abscess is seen in approximately 26-37%. Its treatment is a relevant topic, and the role of the use of antibiotic therapy in its prevention remains controversial, after the publication of several studies with contradictory results and several methodological limitations. Our hypothesis is that the combination of amoxicillin and clavulanic acid will reduce the incidence of anal fistula. METHOD: The aim of this study is to evaluate the efficacy of antibiotherapy after surgical drainage of perianal abscess in the development of perianal fistula. The PERIQxA study is a multicenter, randomized, double-blind controlled trial. The study has been designed to include 286 adult patients who will be randomly (1:1) assigned to either the experimental (amoxicillin/clavulanic acid 875/125 mg TDS for 7 days) or the control arm (placebo). The primary outcome measure is the percentage of patients that develop perianal fistula after surgery and during follow-up (6 months). DISCUSSION: This clinical trial is designed to evaluate the efficacy and safety of amoxicillin/clavulanic in the prevention of perianal fistula. The results of this study are expected to contribute to stablish the potential role of antibiotherapy in the therapeutics for anal abscess. TRIAL REGISTRATION: EudraCT Number: 2021-003376-14. Registered on November 26, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Polaino Moreno V, Caballero-Bermejo AF, Artés Caselles M, et al. Efficacy of amoxicillin/clavulanic acid after surgical drainage of perianal abscess in the prevention of the development of anal fistula (PERIQxA study): study protocol for a multicenter randomized, double-blind clinical trial. Trials. 2024. PMID: 38355562. doi:10.1186/s13063-024-07922-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。